Welcome to our dedicated page for BHG news (Ticker: BHG), a resource for investors and traders seeking the latest updates and insights on BHG stock.
The BHG news page on Stock Titan functions as a historical archive for announcements related to the business that evolved into NeueHealth, Inc. Company communications describe NeueHealth as a value-driven healthcare company that aligns the interests of health consumers, providers, and payors to support high-quality, coordinated care. Over time, these releases trace the shift from a publicly traded structure to a privately held company acquired by an affiliate of New Enterprise Associates (NEA).
Readers can review earnings releases in which NeueHealth reports financial results, discusses Adjusted EBITDA performance, and highlights metrics such as value-based consumers served and enablement services lives. These updates also describe the company’s activity across the ACA Marketplace, Medicare, Medicaid, and ACO REACH arrangements, and explain how its value-driven, consumer-centric care model is applied in these programs.
The archive also includes transaction announcements, such as the December 23, 2024 disclosure of a definitive merger agreement with an NEA affiliate and the October 2, 2025 announcement of the closing of that take-private transaction. Other items include corporate updates like the acquisition of the remaining equity interest in Centrum Health, described as one of NeueHealth’s value-driven clinic brands.
By following this news history, users can see how the company presented its strategy, care model, and financial progress, as well as the steps leading to the cessation of public trading and transition to private ownership. This makes the BHG news page a useful resource for understanding the company’s evolution, rather than a source of ongoing, real-time updates.
NeueHealth (NYSE: NEUE) has completed its previously announced take-private merger with New Enterprise Associates (NEA) in a transaction valued at approximately $1.465 billion. Common stockholders will receive $7.33 per share in cash, while certain stockholders including NEA and 12 existing investors have opted to roll over their shares into the private entity.
The company's executive leadership team, including President and CEO Mike Mikan, will maintain their positions and have agreed to roll over 100% of their equity interests. Following the transaction completion, NeueHealth's common stock ceased trading on the NYSE on October 2, 2025, and the company will terminate its SEC reporting obligations.
NeueHealth (NYSE:NEUE) reported strong Q2 2025 financial results, marking its sixth consecutive quarter of Adjusted EBITDA profitability. The company served approximately 694,000 consumers, representing a 45% increase from Q2 2024.
Key financial metrics for Q2 2025 include revenue of $209.1 million, net income from continuing operations of $6.8 million, and Adjusted EBITDA of $19.0 million. The company's value-based consumers increased to 546,000, up from 364,000 in the previous year, while enablement services lives grew to 148,000 from 113,000.
The company continues to advance its end-to-end, value-based care enablement platform across ACA Marketplace, Medicare, and Medicaid product categories.
NeueHealth (NYSE:NEUE), a value-driven healthcare company, has scheduled its second quarter 2025 earnings conference call for Thursday, August 7, 2025. The company will release its financial results before market open, followed by a conference call at 8:00 AM Eastern Time.
Participants must pre-register online to receive dial-in details. The earnings call will be accessible via webcast through NeueHealth's Investor Relations website at investors.neuehealth.com. A recording of the call and presentation materials will be available on the website after the event.
NeueHealth (NYSE: NEUE) reported its Q1 2025 financial results, marking its fifth consecutive quarter of positive Adjusted EBITDA. The company served approximately 709,000 consumers, representing a 51% increase from Q1 2024. Key metrics show 571,000 value-based consumers (up from 360,000) and 138,000 enablement services lives (up from 109,000).
However, revenue decreased to $215.8 million from $245.1 million in Q1 2024. The company reported a net loss of $10.8 million, compared to a $4.2 million loss in the previous year. Adjusted EBITDA improved significantly to $13.5 million, up from $3.7 million in Q1 2024.
NeueHealth (NYSE: NEUE) has scheduled its first quarter 2025 earnings conference call for May 8, 2025. The company will release its financial results before markets open, followed by a conference call at 8:00 AM Eastern Time.
Participants must pre-register online to receive dial-in details, including their personal access code. The company recommends joining the call 15 minutes early. The earnings presentation will be accessible through NeueHealth's Investor Relations website, with a recording available after the event.
NeueHealth (NYSE: NEUE) has reported its Q4 and full year 2024 financial results, marking its strongest financial performance to date. The company achieved positive Adjusted EBITDA for four consecutive quarters in 2024, demonstrating the success of its value-driven, consumer-centric care model.
Starting 2025, NeueHealth has expanded its consumer base to 717,000, representing a significant 48% increase compared to 2024. The company positions itself for continued strategic growth in 2025, focusing on market expansion and strengthening relationships with payors and providers to deliver a more coordinated care experience.
NeueHealth (NYSE: NEUE) has scheduled its fourth quarter and full year 2024 earnings release for March 20, 2025. The company will announce financial results before market open, followed by a conference call at 8:00 AM Eastern Time.
Participants must pre-register for the telephone conference and will receive access details via email. A webcast option will be available through the company's Investor Relations website at investors.neuehealth.com. The company recommends participants dial in 15 minutes before the call starts. Both the earnings call recording and presentation materials will be accessible on NeueHealth's Investor Relations page after the event.
NeueHealth (NYSE: NEUE) has announced a definitive merger agreement to be acquired by New Enterprise Associates (NEA) at an enterprise value of approximately $1.3 billion. Shareholders will receive $7.33 per share in cash, representing a 70% premium over the December 23, 2024 closing price. Following the transaction, NeueHealth will become privately held, with the current executive team maintaining their roles and rolling over 100% of their equity interests. NEA and 12 existing investors will continue their investments by exchanging shares for new equity interests. The merger includes a 30-day 'go-shop' period expiring January 23, 2025, and is subject to stockholder approval and regulatory clearances.
NeueHealth (NYSE: NEUE) reported Q3 2024 financial results, marking its third consecutive quarter of positive Adjusted EBITDA. Revenue reached $232.9 million in Q3 2024, down from $269.4 million in Q3 2023. The company reported a net loss of $40.4 million, significantly improved from a $547.1 million loss in Q3 2023. Value-Based Consumers served increased to 390,000 from 355,000 year-over-year. The company reaffirmed its 2024 guidance, expecting revenue of approximately $950 million and Adjusted EBITDA between $15-25 million.
NeueHealth (NYSE: NEUE) has announced the acquisition of the remaining 25% equity interest in Centrum Health, making it a wholly owned subsidiary. The transaction aims to simplify NeueHealth's corporate structure and streamline operations to support its value-driven, consumer-centric care model. According to CEO Mike Mikan, this move positions NeueHealth to create a more coordinated healthcare experience. Additional details about the transaction will be disclosed in an upcoming Form 8-K filing with the SEC.
